Tredje AP fonden lessened its holdings in shares of UiPath Inc. (NYSE:PATH – Free Report) by 1.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,458 shares of the healthcare company’s stock after selling 1,057 shares during the quarter. Tredje AP fonden’s holdings in UiPath were worth $843,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of UiPath by 5.6% during the first quarter. Vanguard Group Inc. now owns 40,217,936 shares of the healthcare company’s stock worth $911,741,000 after acquiring an additional 2,133,078 shares in the last quarter. State Board of Administration of Florida Retirement System increased its holdings in UiPath by 0.5% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 295,370 shares of the healthcare company’s stock worth $6,696,000 after purchasing an additional 1,571 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp increased its holdings in UiPath by 4.2% during the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 231,694 shares of the healthcare company’s stock worth $5,240,000 after purchasing an additional 9,393 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of UiPath by 245.1% in the first quarter. Acadian Asset Management LLC now owns 45,700 shares of the healthcare company’s stock worth $1,032,000 after purchasing an additional 32,456 shares during the last quarter. Finally, Neuberger Berman Group LLC lifted its holdings in shares of UiPath by 38.4% in the fourth quarter. Neuberger Berman Group LLC now owns 20,133 shares of the healthcare company’s stock valued at $500,000 after purchasing an additional 5,586 shares in the last quarter. Institutional investors own 62.50% of the company’s stock.
Insider Transactions at UiPath
In other UiPath news, CFO Ashim Gupta sold 47,671 shares of UiPath stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $12.07, for a total transaction of $575,388.97. Following the completion of the sale, the chief financial officer now directly owns 849,917 shares in the company, valued at $10,258,498.19. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 22.37% of the stock is owned by insiders.
Wall Street Analyst Weigh In
View Our Latest Research Report on PATH
UiPath Stock Up 0.3 %
Shares of PATH opened at $12.49 on Friday. UiPath Inc. has a twelve month low of $10.37 and a twelve month high of $27.87. The stock has a market cap of $7.15 billion, a PE ratio of -78.06 and a beta of 0.87. The business’s 50-day moving average price is $12.13 and its 200-day moving average price is $16.01.
UiPath (NYSE:PATH – Get Free Report) last posted its earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.01. The business had revenue of $316.00 million for the quarter, compared to analysts’ expectations of $303.69 million. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.98%. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.09) EPS. Analysts expect that UiPath Inc. will post -0.23 earnings per share for the current fiscal year.
About UiPath
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Featured Stories
- Five stocks we like better than UiPath
- Profitably Trade Stocks at 52-Week Highs
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Why Are These Companies Considered Blue Chips?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Upcoming IPO Stock Lockup Period, Explained
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding PATH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UiPath Inc. (NYSE:PATH – Free Report).
Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.